Gelmon K - Search Results

1

The ability of cancer-specific and generic preference-based instruments to discriminate across clinical and self-reported measures of cancer severities.

Teckle P, Peacock S, McTaggart-Cowan H, van der Hoek K, Chia S, Melosky B, Gelmon K. Teckle P, et al. Among authors: gelmon k. Health Qual Life Outcomes. 2011 Nov 28;9:106. doi: 10.1186/1477-7525-9-106. Health Qual Life Outcomes. 2011. PMID: 22123196 Free PMC article.

2

Mapping the FACT-G cancer-specific quality of life instrument to the EQ-5D and SF-6D.

Teckle P, McTaggart-Cowan H, Van der Hoek K, Chia S, Melosky B, Gelmon K, Peacock S. Teckle P, et al. Among authors: gelmon k. Health Qual Life Outcomes. 2013 Dec 1;11:203. doi: 10.1186/1477-7525-11-203. Health Qual Life Outcomes. 2013. PMID: 24289488 Free PMC article. Clinical Trial.

3

Pegylated liposomal doxorubicin and trastuzumab in HER-2 overexpressing metastatic breast cancer: a multicenter phase II trial.

Chia S, Clemons M, Martin LA, Rodgers A, Gelmon K, Pond GR, Panasci L. Chia S, et al. Among authors: gelmon k. J Clin Oncol. 2006 Jun 20;24(18):2773-8. doi: 10.1200/JCO.2005.03.8331. Epub 2006 May 8. J Clin Oncol. 2006. PMID: 16682726 Clinical Trial.

4

A Phase Ib Trial of Durvalumab in Combination with Trastuzumab in HER2-Positive Metastatic Breast Cancer (CCTG IND.229).

Chia S, Bedard PL, Hilton J, Amir E, Gelmon K, Goodwin R, Villa D, Cabanero M, Tu D, Tsao M, Seymour L. Chia S, et al. Among authors: gelmon k. Oncologist. 2019 Nov;24(11):1439-1445. doi: 10.1634/theoncologist.2019-0321. Epub 2019 Aug 16. Oncologist. 2019. PMID: 31420468 Free PMC article. Clinical Trial.

5

Pan-cancer analysis of advanced patient tumors reveals interactions between therapy and genomic landscapes.

Pleasance E, Titmuss E, Williamson L, Kwan H, Culibrk L, Zhao EY, Dixon K, Fan K, Bowlby R, Jones MR, Shen Y, Grewal JK, Ashkani J, Wee K, Grisdale CJ, Thibodeau ML, Bozoky Z, Pearson H, Majounie E, Vira T, Shenwai R, Mungall KL, Chuah E, Davies A, Warren M, Reisle C, Bonakdar M, Taylor GA, Csizmok V, Chan SK, Zong Z, Bilobram S, Muhammadzadeh A, D'Souza D, Corbett RD, MacMillan D, Carreira M, Choo C, Bleile D, Sadeghi S, Zhang W, Wong T, Cheng D, Brown SD, Holt RA, Moore RA, Mungall AJ, Zhao Y, Nelson J, Fok A, Ma Y, Lee MKC, Lavoie JM, Mendis S, Karasinska JM, Deol B, Fisic A, Schaeffer DF, Yip S, Schrader K, Regier DA, Weymann D, Chia S, Gelmon K, Tinker A, Sun S, Lim H, Renouf DJ, Laskin J, Jones SJM, Marra MA. Pleasance E, et al. Among authors: gelmon k. Nat Cancer. 2020 Apr;1(4):452-468. doi: 10.1038/s43018-020-0050-6. Epub 2020 Apr 13. Nat Cancer. 2020. PMID: 35121966

6

The presence of stromal mast cells identifies a subset of invasive breast cancers with a favorable prognosis.

Dabiri S, Huntsman D, Makretsov N, Cheang M, Gilks B, Bajdik C, Gelmon K, Chia S, Hayes M. Dabiri S, et al. Among authors: gelmon k. Mod Pathol. 2004 Jun;17(6):690-5. doi: 10.1038/modpathol.3800094. Mod Pathol. 2004. PMID: 15044916 Free article.

7

Phase II trial of OGX-011 in combination with docetaxel in metastatic breast cancer.

Chia S, Dent S, Ellard S, Ellis PM, Vandenberg T, Gelmon K, Powers J, Walsh W, Seymour L, Eisenhauer EA. Chia S, et al. Among authors: gelmon k. Clin Cancer Res. 2009 Jan 15;15(2):708-13. doi: 10.1158/1078-0432.CCR-08-1159. Clin Cancer Res. 2009. PMID: 19147778 Clinical Trial.

8

Cost-effectiveness of annual versus biennial screening mammography for women with high mammographic breast density.

Pataky R, Ismail Z, Coldman AJ, Elwood M, Gelmon K, Hedden L, Hislop G, Kan L, McCoy B, Olivotto IA, Peacock S. Pataky R, et al. Among authors: gelmon k. J Med Screen. 2014 Dec;21(4):180-8. doi: 10.1177/0969141314549758. Epub 2014 Sep 3. J Med Screen. 2014. PMID: 25186116

9

Association Between Regional Nodal Irradiation and Breast Cancer Recurrence-Free Interval for Patients With Low-Risk, Node-Positive Breast Cancer.

Sit D, Lalani N, Chan E, Tran E, Speers C, Gondara L, Chia S, Gelmon K, Lohrisch C, Nichol A. Sit D, et al. Among authors: gelmon k. Int J Radiat Oncol Biol Phys. 2022 Mar 15;112(4):861-869. doi: 10.1016/j.ijrobp.2021.10.149. Epub 2021 Nov 8. Int J Radiat Oncol Biol Phys. 2022. PMID: 34762971 Clinical Trial.

10

Human epidermal growth factor receptor 2 overexpression as a prognostic factor in a large tissue microarray series of node-negative breast cancers.

Chia S, Norris B, Speers C, Cheang M, Gilks B, Gown AM, Huntsman D, Olivotto IA, Nielsen TO, Gelmon K. Chia S, et al. Among authors: gelmon k. J Clin Oncol. 2008 Dec 10;26(35):5697-704. doi: 10.1200/JCO.2007.15.8659. Epub 2008 Nov 10. J Clin Oncol. 2008. PMID: 19001334

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

367 results

Search Page